Cargando…

A Review of FLT3 Kinase Inhibitors in AML

Acute myeloid leukemia (AML) is a highly aggressive illness distinguished by the accumulation of abnormal hematopoietic precursors in both the bone marrow and peripheral blood. The prevalence of FLT3 gene mutations is high and escalates the probability of relapse and mortality. The survival rates fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Negotei, Cristina, Colita, Andrei, Mitu, Iuliana, Lupu, Anca Roxana, Lapadat, Mihai-Emilian, Popovici, Constanta Elena, Crainicu, Madalina, Stanca, Oana, Berbec, Nicoleta Mariana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607239/ https://www.ncbi.nlm.nih.gov/pubmed/37892567 http://dx.doi.org/10.3390/jcm12206429

Ejemplares similares

APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania
por: Berbec, Nicoleta Mariana, et al.
Publicado: (2018)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Etiopathogenesis and prognostic implications of autoimmune hemolytic anemia association with chronic lymphocytic leukemia B
por: Oprea, MM, et al.
Publicado: (2012)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

Delineation of Molecular Lesions in Acute Myeloid Leukemia Patients at Diagnosis: Integrated Next Generation Sequencing and Cytogenomic Studies
por: Papuc, Sorina Mihaela, et al.
Publicado: (2021)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD(+) AML cell growth
por: Weir, Mark C., et al.
Publicado: (2017)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Increased Dkk‐1 plasma levels may discriminate disease subtypes in myeloproliferative neoplasms
por: Mambet, Cristina, et al.
Publicado: (2018)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Microenvironmental Hypoxia regulates FLT3 expression and biology in AML
por: Sironi, Silvia, et al.
Publicado: (2015)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
por: Loschi, Michael, et al.
Publicado: (2021)

Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma—Romanian Experience
por: Tanase, Alina D., et al.
Publicado: (2020)

Real-World Evidence: The Low Validity of Temperature Screening for COVID-19 Triage
por: Pană, Bogdan C., et al.
Publicado: (2021)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
por: Short, Nicholas J., et al.
Publicado: (2023)

Tumor microenvironment in Hodgkin lymphoma: novel prognostic factors for assessing disease evolution
por: Turbatu, Andrei, et al.
Publicado: (2023)

Targeting FLT3 mutations in AML: review of current knowledge and evidence
por: Daver, Naval, et al.
Publicado: (2019)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Perspectives on the co-treatment with GnRHa in female patients undergoing hematopoietic stem cell transplantation
por: Cima, Luminita Nicoleta, et al.
Publicado: (2017)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy
por: Coles, EC, et al.
Publicado: (2012)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
por: Engen, Caroline Benedicte Nitter, et al.
Publicado: (2014)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

Postanesthetic skin erythema due to succinylcholine versus atracurium
por: Ciobotaru, Oana Roxana, et al.
Publicado: (2020)

New Functional Ingredients Based on Microencapsulation of Aqueous Anthocyanin-Rich Extracts Derived from Black Rice (Oryza sativa L.)
por: Aprodu, Iuliana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pvtfcoalg3uj467n0bi5a9uqja